Welcome to our dedicated page for Clearmind Medicine SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clearmind Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clearmind Medicine's regulatory disclosures and financial reporting.
Clearmind Medicine reports that its proprietary compound MEAI (5-MeO-AI), a next-generation, non-hallucinogenic neuroplastogen, has been specifically named in new bipartisan U.S. legislation, the Expanding Veterans’ Access to Emerging Treatments Act of 2026 (H.R. 7091).
The bill would direct the U.S. Department of Veterans Affairs to create investigational research and extended access treatment programs using emerging therapies for unmet medical needs in veterans. Covered therapies include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine and others designated by the VA Secretary.
This is the first time MEAI has been referenced in U.S. federal legislation. Clearmind highlights potential applications for conditions such as Alcohol Use Disorder and post-traumatic stress disorder, emphasizing growing policy recognition of innovative, evidence-based psychedelic and neuroplastogen approaches.
Clearmind Medicine Inc. is updating its registration to cover the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are held by institutional selling shareholders from a January 2024 private placement and prior related financings, and represent a significant portion of the company’s 1,499,838 common shares outstanding as of January 26, 2026.
The company will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if all related warrants are exercised for cash at their current exercise price. A risk factor highlights that resale of these shares, equal to about 22.13% of outstanding shares as of January 26, 2026, could pressure the market price, and notes additional geopolitical risks tied to Clearmind’s operations and personnel presence in Israel.
Clearmind Medicine Inc. filed a post-effective amendment that updates prior registration statements covering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE warrants. These shares are being registered for selling shareholders from a January 2024 private placement and may be sold from time to time on Nasdaq or in negotiated deals. Clearmind will not receive proceeds from any resale of these shares, but could receive up to approximately $1.3 million if the PIPE warrants are fully exercised for cash. As of January 26, 2026, Clearmind had 1,499,838 common shares outstanding, and full exercise of the registered PIPE warrants would increase this to 1,831,787 shares. The filing notes that the 331,949 warrant shares equal about 22.13% of common shares outstanding before this offering, highlighting potential resale overhang for existing shareholders.
Clearmind Medicine Inc. is updating a prior registration and converting it to a Form F-3 to allow the resale of up to 296,130 common shares by existing holders. These shares include 294,969 shares tied to convertible promissory notes and 1,161 shares granted as equity awards. Clearmind has already issued promissory notes with an aggregate principal of $2.5 million, all of which, plus accrued interest, have been converted into 129,287 common shares as of January 26, 2026. The notes convert at the lower of a fixed price of $40.40 or 88% of recent VWAP, but not below a floor of $8.00. Clearmind will not sell any shares in this resale and will not receive proceeds from selling shareholders, though it may receive up to an additional $6.75 million in gross proceeds if it elects to issue more notes under the purchase agreements. Shares outstanding were 1,499,838 as of January 26, 2026, and would be 1,795,968 if all registered note shares are issued.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company focused on psychedelic-based therapies, files its annual Form 20-F reporting continued operating losses and substantial going concern uncertainty. The company recorded operating losses of $5,667,177, $5,744,925 and $6,303,434 for the years ended October 31, 2025, 2024 and 2023, with net losses of $3,856,983, $5,254,678 and $8,620,837, and an accumulated deficit of $27,879,724 as of October 31, 2025.
The auditors include an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, noting negative operating cash flows of $4,734,498 and reliance on future equity or debt financing. Clearmind reports cash and cash equivalents of $3,923,058 as of October 31, 2025 and remains pre-revenue with no approved products, advancing lead candidate MEAI through early-stage clinical development for alcohol use disorder and other indications under significant regulatory, clinical, funding and commercialization risks.
Clearmind Medicine Inc. filed a Form 6-K to furnish a press release announcing that treatment is complete for all six patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder. This multinational study at sites including Johns Hopkins University and leading Israeli medical centers is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with moderate to severe alcohol use disorder.
The company notes that the first cohort previously showed a favorable safety profile and early signals of benefit, such as reduced cravings and withdrawal symptoms. Clearmind describes this second-cohort completion as steady progress in the program and indicates that topline results from this cohort are anticipated in the coming months.